Navigation Links
Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting
Date:10/29/2009

MOUNTAIN VIEW, Calif., Oct. 29 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that additional data on Qnexa(TM), an investigational drug candidate for obesity, was presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley W. Day, PhD, vice president of clinical development at VIVUS, presented the additional data from the company's two year-long phase 3 obesity trials during the Pharmacotherapy Update portion of the pre-conference on October 24, 2009. Top-line results from the phase 3 studies were previously reported in September 2009. The presentation included data from the EQUIP (OB-302) and CONQUER (OB-303) studies that further supports the safety and efficacy profile of Qnexa.

The additional efficacy data from the EQUIP study that was presented included weight loss by BMI category, on an intent-to-treat, last observation carried forward (ITT-LOCF) basis for full dose Qnexa.

                     Percent Weight Loss (ITT-LOCF)
                     ------------------------------

    Baseline BMI                Placebo             Full Dose Qnexa
    ------------                -------             ---------------
    >35-40                        1.8%                    10.7%
    >40-45                        1.3%                    11.1%
    >45-50                        1.0%                    11.8%
    >50                           2.0%                    10.3%

"The EQUIP study was designed to look at the effect of Qnexa on morbidly obese patients, that is, those patients with a baseline BMI of 35 or greater. The average baseline BMI in the EQUIP study was 42.1. A review of results by baseline BMI show a consistent effect across a broad range of patients based on starting body weight," stated Wesley W. Day. "On an ITT-LOCF basis,
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
3. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
4. PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
5. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
6. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
7. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
8. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
9. Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
10. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
11. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Equity Research highlights Epizyme (Nasdaq: EPZM - Free Report ... PNRA - Free Report ) as the Bear of the Day. ... FOLD - Free Report ), Sanofi (NYSE: SNY - ... ). Here is a synopsis of all five stocks: ... The biotech bull market is far from over due to ...
(Date:8/22/2014)...  - MediaLINC unlocks the real ... general availability of MediaLINC - its innovative ... education, entertainment and clinical content direct to standard HD ... " Lincor has already been phenomenally ... bedside smart devices, " comments Dan Byrne , ...
(Date:8/22/2014)... Calif. , Aug. 22, 2014  WaferGen Bio-systems, ... underwritten public offering of units of common stock and ... gross proceeds of $20 million, prior to deducting underwriting ... Company.  The shares and warrants are immediately separable and ... are expected to begin trading on The NASDAQ Stock ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Lincor Unveils Next Generation TV-based Patient Engagement Solution 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... MOSCOW, Nov. 16, 2011 The Nutrilite Health Institute ... a U.S.-Russia collaboration demonstrating that overweight Russian adults have ... may be linked to poor long-term health outcomes. The ... extend beyond the initial findings presented in late 2010 ...
... Medical, Inc., (OTCBB:AEMD) disclosed today that its Chairman and ... to shareholders. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b ) ... year, we introduced and began marketing the Aethlon ADAPT™ ... and drug world to establish a new class of ...
Cached Medicine Technology:Russian Institute of Nutrition-Nutrilite Health Institute Collaboration Identifies Stress Markers Potentially Linked to Chronic Diseases in Overweight Russian Adults 2Russian Institute of Nutrition-Nutrilite Health Institute Collaboration Identifies Stress Markers Potentially Linked to Chronic Diseases in Overweight Russian Adults 3Russian Institute of Nutrition-Nutrilite Health Institute Collaboration Identifies Stress Markers Potentially Linked to Chronic Diseases in Overweight Russian Adults 4Aethlon Medical Releases Shareholder Letter 2Aethlon Medical Releases Shareholder Letter 3Aethlon Medical Releases Shareholder Letter 4Aethlon Medical Releases Shareholder Letter 5Aethlon Medical Releases Shareholder Letter 6Aethlon Medical Releases Shareholder Letter 7
(Date:8/22/2014)... 2014 As the controversy surrounding ... in uterine surgeries continues to grow, Bernstein Liebhard ... decided to limit coverage of uterine morcellation. According ... Cross-Blue Shield of Massachusetts will no longer cover ... as of September 1, 2014. Other insurers in ...
(Date:8/22/2014)... Natural Clear Vision , a how-to guide and ... from legally blind to perfect 20/20 vision has caught the ... “There is a huge portion of the population today that ... people just think that’s the way it will always be ... pretty risky at times,” reports Michaels. “This program is a ...
(Date:8/22/2014)... August 22, 2014 Mi40x , the ... research to show people how they can use a simple ... only a matter of weeks has caught the attention of ... is one of the most well-known bodybuilders in the industry, ... he has today, that in itself is a testament to ...
(Date:8/22/2014)... DENVER For the first time an oncogenic somatic ... during transfection) protein has been identified in small cell ... mutation within SCLC cell lines produced increased intracellular signaling ... form of lung cancer representing 15% of all lung ... representing 85% of lung cancer, has been extensively examined ...
(Date:8/22/2014)... complex autoimmune disease that affects 1 to 2 ... cope with pain, disability and joint disfigurements, but ... life and marital functioning. While many pharmacological advances ... is common. In addition, some patients avoid newer ... effects. Because of this, there is interest in ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2
... in two years, California researcher says , , FRIDAY, Feb. 1 ... the progress of the disease in 90 percent of the ... turned the cancer into a chronic, manageable disease," said W. ... Feb. 1 issue of Cancer Research . , Twenty ...
... The globally active precious,metal and technology group Heraeus ... Interventional Business of Synovis Life,Technologies, Inc., based in ... 31, 2008. With this acquisition, the Heraeus Medical,Components ... facilities in the,U.S., Germany, Switzerland and Puerto Rico., ...
... 1 Lifespring Health,sponsors the Kaiser Permanente San Francisco ... charity event benefiting the Hemophilia Foundation of,Northern California, Support ... House., Set to take place on Feb. 3, ... course is ranked as one of the most scenic,in ...
... Piwek to Assist in Generating New Retail Licensing ... Inc. (OTC,Bulletin Board: SKVI) ( http://www.skinvisible.com ), a ... patented dermatology,products with their proprietary polymer delivery system ... selected as a new member of,the Company,s Board ...
... and vigilance show a relationship with core body temperature ... high during the daytime, skin temperature is low, which ... temperature is low at night time, skin temperature is ... suffering from narcolepsy, however, direct manipulations of their skin ...
... , UCLA and University of North Carolina researchers have found ... sexual and/or physical abuse may have a heightened brain response ... IBS is a condition that affects 10 to 15 percent ... constipation or both. , Researchers used brain ...
Cached Medicine News:Health News:Experimental Vaccine Halts Prostate Cancer in Mice 2Health News:Experimental Vaccine Halts Prostate Cancer in Mice 3Health News:Heraeus Strengthens Medical Components Business 2Health News:Skinvisible Appoints New Board Member 2Health News:Skinvisible Appoints New Board Member 3Health News:Changes in narcoleptics' skin, core body temperatures affect their vigilance and sleepiness 2Health News:Changes in narcoleptics' skin, core body temperatures affect their vigilance and sleepiness 3
... Introducing the new PRONEB® ULTRA compressor. This ... time while delivering more medication to the ... LC PLUS® or PARI LC STAR® Reusable ... optimized for inhalation and retention into the ...
... PRONEB® ULTRA compressor. This high output compressor ... more medication to the patient's lungs. When ... PARI LC STAR® Reusable Nebulizer, the particle ... and retention into the lungs. With less ...
... The new PARI TREK™ Compact Compressor ... take their aerosol treatments anywhere and everywhere. ... powerful. Three versatile power source optionsworldwide AC ... and rechargeable battery, permit patients the freedom ...
... Air., ,Allied Healthcares Timeter® PCS 414 portable ... air compressors that you may wonder if its ... 414 features a durable, mar-resistant steel case thats ... weighs only 26.5 pounds. The PCS 414 has ...
Medicine Products: